SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001479290-20-000114
Filing Date
2020-12-22
Accepted
2020-12-22 17:27:18
Documents
14
Period of Report
2020-12-18
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K rvnc-20201218.htm   iXBRL 8-K 35558
  Complete submission text file 0001479290-20-000114.txt   177823

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20201218.xsd EX-101.SCH 2458
3 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rvnc-20201218_cal.xml EX-101.CAL 744
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rvnc-20201218_def.xml EX-101.DEF 1689
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20201218_lab.xml EX-101.LAB 24275
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20201218_pre.xml EX-101.PRE 12680
7 EXTRACTED XBRL INSTANCE DOCUMENT rvnc-20201218_htm.xml XML 11310
Mailing Address 7555 GATEWAY BLVD. NEWARK CA 94560
Business Address 7555 GATEWAY BLVD. NEWARK CA 94560 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 201409036
SIC: 2834 Pharmaceutical Preparations